CEBPD suppresses prolactin expression and prolactinoma cell proliferation

Molecular Endocrinology

Volumn 25, Issue 11, 2011, Pages 1880-1891

  Tong, Yunguang ^a   Zhou, Jin ^b   Mizutani, Jun ^a   Fukuoka, Hidenori ^a   Ren, Song Guang ^a   Gutierrez Hartmann, Arthur ^c   Phillip Koeffler, H ^a   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN DELTA; CYCLIN B1; CYCLIN B2; CYCLIN D1; ESTROGEN; ESTROGEN RECEPTOR ALPHA; PROLACTIN; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR PIT 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROLACTIN SECRETING CELL; PROLACTINOMA; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; TUMOR CELL; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYCLIN B1; CYCLIN B2; CYCLIN D1; ESTROGENS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GROWTH HORMONE; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROLACTIN; PROLACTINOMA; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; RADIOIMMUNOASSAY; RATS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR PIT-1;

RATTUS;

EID: 80054983925     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1075     Document Type: Article

References (42)

1. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA 2011 Diagnosis and treatment of hy-perprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273-288
2. Stefaneanu L, Kovacs K, Lloyd RV, Scheithauer BW, Young Jr WF, Sano T, Jin L 1992 Pituitary lactotrophs and somatotrophs in pregnancy: a correlative in situ hybridization and immunocytochemical study. Virchows Arch B Cell Pathol Incl Mol Pathol 62:291-296
3. Haggi ES, Torres AI, Maldonado CA, Aoki A 1986 Regression of redundant lactotrophs in rat pituitary gland after cessation of lactation. J Endocrinol 111:367-373
4. Ben-Jonathan N, LaPensee CR, LaPensee EW 2008 What can we learn from rodents about prolactin in humans? Endocr Rev 29: 1-41
5. Scully KM, Jacobson EM, Jepsen K, Lunyak V, Viadiu H, Carriere C, Rose DW, Hooshmand F, Aggarwal AK, Rosenfeld MG 2000 Allosteric effects of Pit-1 DNA sites on long-term repression in cell type specification. Science 290:1127-1131
6. Drouin J 2006 Molecular mechanisms of pituitary differentiation and regulation: implications for hormone deficiencies and hormone resistance syndromes. Front Horm Res 35:74-87
7. Pfaffle R, Klammt J 2011 Pituitary transcription factors in the aetiology of combined pituitary hormone deficiency. Best Pract Res Clin Endocrinol Metab 25:43-60
8. Schaufele F 1999 Regulation of estrogen receptor activation of the prolactin enhancer/promoter by antagonistic activation function-2-interacting proteins. Mol Endocrinol 13:935-945
9. Duval DL, Jean A, Gutierrez-Hartmann A 2003 Ras signaling and transcriptional synergy at a flexible Ets-1/Pit-1 composite DNA element is defined by the assembly of selective activation domains. J Biol Chem 278:39684-39696
10. Schweppe RE, Gutierrez-Hartmann A 2001 Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter. Nucleic Acids Res 29:1251-1260
11. Sarkar DK 2006 Genesis of prolactinomas: studies using estrogen-treated animals. Front Horm Res 35:32-49
12. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S 1999 Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317-1321
13. De Paul AL, Gutierrez S, Sabatino ME, Mukdsi JH, Palmeri CM, Soaje M, Petiti JP, Torres AI 2011 Epidermal growth factor induces a sexually dimorphic proliferative response of lactotroph cells through PKC/ERK1/2/Pit-1 in vitro. Exp Physiol 96:226-239
14. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG, Melmed S 2008 Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res 68:6377-6386
15. Radl DB, Ferraris J, Boti V, Seilicovich A, Sarkar DK, Pisera D 2011 Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor. PLoS One 6:e18097
16. Gruszka A, Ren SG, Dong J, Culler MD, Melmed S 2007 Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 148:6107-6114
17. Spady TJ, Pennington KL, McComb RD, Shull JD 1999 Genetic bases of estrogen-induced pituitary growth in an intercross between the ACI and Copenhagen rat strains: dominant mendelian inheritance of the ACI phenotype. Endocrinology 140:2828-2835
18. Evans CO, Moreno CS, Zhan X, McCabe MT, Vertino PM, De-siderio DM, Oyesiku NM 2008 Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary 11:231-245
19. Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP 2005 C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene 24:1589-1597
20. Melmed S 2011 Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7:257-266
21. Ramji DP, Foka P 2002 CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 365:561-575
22. Li YC, Hayes S, Young AP 1994 Transactivation of the 'promoter-less' luciferase-encoding vectors pXP1 and pXP2 by C/EBP a. Gene 138:257-258
23. Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, Taguchi H, Koeffler HP 2005 CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-re-sponsive prostate cancer LNCaP cells. Cancer Res 65:4762-4768
24. Sivko GS, DeWille JW 2004 CCAAT/Enhancer binding protein & (c/EBPS) regulation and expression in human mammary epithelial cells. I. "Loss of function" alterations in the c/EBPS growth inhibitory pathway in breast cancer cell lines. J Cell Biochem 93:830-843
25. Delhase M, Vergani P, Malur A, Hooghe-Peters EL, Hooghe RJ 1993 The transcription factor Pit-1/GHF-1 is expressed in hemopoietic and lymphoid tissues. Eur J Immunol 23:951-955
26. Bamberger AM, Bamberger CM, Pu LP, Puy LA, Loh YP, Asa SL 1995 Expression of pit-1 messenger ribonucleic acid and protein in the human placenta. J Clin Endocrinol Metab 80:2021-2026
27. Gil-Puig C, Blanco M, Garcia-Caballero T, Segura C, Perez-Fernandez R 2002 Pit-1/GHF-1 and GH expression in the MCF-7 human breast adenocarcinoma cell line. J Endocrinol 173:161-167
28. Gil-Puig C, Seoane S, Blanco M, Macia M, Garcia-Caballero T, Segura C, Perez-Fernandez R 2005 Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation. Eur J Endocrinol 153:335-344
29. Guidi CJ, Mudhasani R, Hoover K, Koff A, Leav I, Imbalzano AN, Jones SN 2006 Functional interaction of the retinoblastoma and Ini1/Snf5 tumor suppressors in cell growth and pituitary tumori-genesis. Cancer Res 66:8076-8082
30. Lazzerini Denchi E, Attwooll C, Pasini D, Helin K 2005 Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 25:2660-2672
31. Herenu CB, Morel GR, Bellini MJ, Reggiani PC, Sosa YE, Brown OA, Goya RG 2006 Gene therapy in the neuroendocrine system. Front Horm Res 35:135-142
32. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Wein-berg RA 1992 Effects of an Rb mutation in the mouse. Nature 359:295-300
33. Kim JK, Diehl JA 2009 Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 220:292-296
34. Miyazaki T, Arai S 2007 Two distinct controls of mitotic cdk1/ cyclin B1 activity requisite for cell growth prior to cell division. Cell Cycle 6:1419-1425
35. Gong D, Ferrell Jr JE 2010 The roles of cyclin A2, B1, and B2 in early and late mitotic events. Mol Biol Cell 21:3149-3161
36. Bradford AP, Conrad KE, Wasylyk C, Wasylyk B, Gutierrez-Hart-mann A 1995 Functional interaction of c-Ets-1 and GHF-1/Pit-1 mediates Ras activation of pituitary-specific gene expression: mapping of the essential c-Ets-1 domain. Mol Cell Biol 15:2849-2857
37. Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJ, Kenyon L, Visone R, De Martino I, Ciarmiello A, Arra C, Viglietto G, Croce CM, Fusco A 2005 Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hor-mone/prolactin cell pituitary adenomas and natural killer cell lym-phomas. Oncogene 24:3427-3435
38. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, Fusco A 2002 Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21:3190-3198
39. Fedele M, Pierantoni GM, Visone R, Fusco A 2006 E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div 1:17
40. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cap-pabianca P, Chiappetta G, Forzati F, Lombardi G, Colao A, Trouil-las J, Fedele M, Fusco A 2009 HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res 69: 1844-1850
41. Strecker TE, Spady TJ, Schaffer BS, Gould KA, Kaufman AE, Shen F, McLaughlin MT, Pennington KL, Meza JL, Shull JD 2005 Genetic bases of estrogen-induced pituitary tumorigenesis: identification of genetic loci determining estrogen-induced pituitary growth in reciprocal crosses between the ACI and Copenhagen rat strains. Genetics 169:2189-2197
42. Imaizumi M, Kondo T, Taguchi T, Hattori T, Abe O, Kitano M, Wakui A 1993 A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors. Surg Today 23:412-419